Medications for Attention Deficit Hyperactivity Disorder (ADHD)
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Attention Deficit Hyperactivity Disorder (ADHD).
Found 6 Approved Drugs for Attention Deficit Hyperactivity Disorder (ADHD)
Methylphenidate
Brand Names
Relexxii, Jornay, Methylin, Quillivant, QuilliChew, Methylphenidate Transdermal, Cotempla, Daytrana, Metadate, Aptensio, Ritalin, Concerta
Methylphenidate
Brand Names
Relexxii, Jornay, Methylin, Quillivant, QuilliChew, Methylphenidate Transdermal, Cotempla, Daytrana, Metadate, Aptensio, Ritalin, Concerta
Form: Patch, Tablet, Suspension, Capsule, Solution
Method of administration: Oral, Transdermal
FDA approval date: December 31, 1955
Classification: Central Nervous System Stimulant
Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), in pediatric patients 6 to 12 years of age. Methylphenidate hydrochloride extended-release capsule is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 12 years of age ( 1 ).
Intuniv
Generic Name
Guanfacine
Intuniv
Generic Name
Guanfacine
Form: Tablet
Method of administration: Oral
FDA approval date: October 17, 1995
Classification: Central alpha-2 Adrenergic Agonist
Guanfacine hydrochloride tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.
Clonidine
Brand Names
Nexiclon, Catapres-TTS-1, ONYDA, Duraclon, Clonidine Transdermal, Catapres-TTS-2, Catapres-TTS-3, Clonidine HCI
Clonidine
Brand Names
Nexiclon, Catapres-TTS-1, ONYDA, Duraclon, Clonidine Transdermal, Catapres-TTS-2, Catapres-TTS-3, Clonidine HCI
Form: Patch, Injection, Tablet, Suspension
Method of administration: Epidural, Oral, Intravenous, Transdermal
FDA approval date: January 03, 1995
Classification: Central alpha-2 Adrenergic Agonist
Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. Clonidine hydrochloride is a centrally acting alpha 2 -adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Vyvanse
Generic Name
Lisdexamfetamine Dimesylate
Vyvanse
Generic Name
Lisdexamfetamine Dimesylate
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: February 23, 2007
Classification: Central Nervous System Stimulant
Lisdexamfetamine dimesylate capsules and lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies ( 1.
Dexmethylphenidate
Brand Names
Azstarys, Focalin
Dexmethylphenidate
Brand Names
Azstarys, Focalin
Form: Tablet, Capsule
Method of administration: Oral
FDA approval date: November 30, 2001
Classification: Central Nervous System Stimulant
Dexmethylphenidate hydrochloride tablets is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Dexmethylphenidate hydrochloride tablets is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Showing 1-5 of 6
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances